Tokyo, Japan, Japan · Est. 2005 · 20,000 employees
Astellas Pharma is a Japanese pharmaceutical company focused on innovative treatments in oncology, immunology, and other therapeutic areas through research and development.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 8 drugs with upcoming expirations
Pipeline
By Phase
14 drugs in development
By Therapeutic Area
top 6
R&D Momentum
74/100
Pipeline Velocity
43/100
Trial Completion Rate
91/100
Pipeline Concentration
16/100
Pipeline Freshness
69/100
Strategic Signals
Activity
Last 14 days
A Safety Surveillance Study of Events of Special Interest Occurring in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy
A Randomized, Open-label, Phase 3 Study of Setidegrasib (ASP3082) Versus Docetaxel in Participants With KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum Based Chemotherapy and Checkpoint Inhibitor Therapy (CPI)
A Phase 1 Study of ASP3082 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation
A Phase 1/2 Multicenter, Open-label, Dose Escalation Study Followed by a Randomized, Double-blind Sham-controlled Dose Expansion Study to Evaluate the Safety, Tolerability and Efficacy of ASP2246 in Adult Participants Who Have Motor Dysfunction Associated With Late Subacute to Chronic Ischemic Stroke Due to Supratentorial Perforator Area Infarction
Use-result Surveillance for PADCEV Injection 20 mg and 30 mg (Enfortumab Vedotin) in South Korea
Post-marketing Observational Study of VYLOY (Zolbetuximab) Injection 100 mg, 300 mg for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in South Korea
A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From a Prograf® Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf® Based Immunosuppressive Regimen, Including a Long-Term Follow-Up
A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants With Advanced Prostate Cancer
A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY
A Phase 1b/2 Open-label Study to Assess the Safety and Efficacy of ASP546C in Participants With CLDN18.2-expressing Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Pancreatic Adenocarcinoma or Other Solid Tumor Types
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY™) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
Details
Company Overview
$55.0B
Mkt Cap
$13.2B
Revenue
—
Cash
Therapeutic Focus
Pipeline
Regulatory
Cefizox — CEFIZOX
Application NDA050560 (NDA)
Cefizox — CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER
Application NDA050589 (NDA)
Adenocard — ADENOCARD
Application NDA019937 (NDA)
Adenocard — ADENOSCAN
Application NDA020059 (NDA)
VESIcare — VESICARE
Application NDA021518 (NDA)
Lexiscan — LEXISCAN
Application NDA022161 (NDA)
Xtandi — XTANDI
Application NDA203415 (NDA)
Myrbetriq — MYRBETRIQ
Application NDA202611 (NDA)
Cresemba — CRESEMBA
Application NDA207501 (NDA)
Xospata — XOSPATA
Application NDA211349 (NDA)
Xtandi — XTANDI
Application NDA213674 (NDA)
VESIcare — VESICARE LS
Application NDA209529 (NDA)
Myrbetriq — MYRBETRIQ GRANULES
Application NDA213801 (NDA)
Cresemba — CRESEMBA
Application NDA207500 (NDA)
Izervay — IZERVAY
Application NDA217225 (NDA)
Veozah — VEOZAH
Application NDA216578 (NDA)
VYLOY — VYLOY
Application BLA761365 (BLA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)